SEARCH

SEARCH BY CITATION

References

  • 1
    Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-α-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68:556567. MEDLINE
  • 2
    Talpaz M, Cortes J, O'Brien S, Keating M, Giles F, Rose E, Rybak ME, et al. Phase I study of polyethylene glycol (PEG) interferon alpha-2b (Intron A) in CML patients [Abstract]. Blood 1998; 92(Suppl):251A.
  • 3
    Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. Hepatology 2000; 32:647653. MEDLINE
  • 4
    Lindsay KL, Trepo C, Heintges T, Schiffman M, Gordon S, Hoefs J, Schiff E, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395403. MEDLINE
  • 5
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:16661672. MEDLINE
  • 6
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:14851492. MEDLINE
  • 7
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. for the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:14261432. MEDLINE
  • 8
    EASL International Consensus Conference on Hepatitis C: Paris, 26-28 February 1999. Consensus statement. J Hepatol 1999; 30:956961. MEDLINE
  • 9
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b in combination with ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomised trial. Lancet 2001; 358; 958965. MEDLINE
  • 10
    Carithers RL Jr, Zeuzem S, Manns MP, McHutchison JG, Perrillo RP, Bailey R, Ling M-H, et al. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin [Abstract]. Hepatology 2000; 32:317A.
  • 11
    Martell M, Gómez J, Esteban JI, Sauleda S, Quer J, Cabot B, Esteban R, et al. High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol 1999; 37:327332. MEDLINE
  • 12
    Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of Hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26:226231. MEDLINE
  • 13
    Zeuzem S, Lee J-H, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27:11491156. MEDLINE
  • 14
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28:960964. MEDLINE
  • 15
    Zeuzem S, Schmidt JM, Lee JH, Von Wagner M, Teuber G, Roth WK. Hepatitis C dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28:245252. MEDLINE
  • 16
    Zeuzem S. Clinical implications of hepatitis C viral kinetics. J Hepatol 1999; 31(Suppl 1):6164. MEDLINE
  • 17
    Layden TJ. Principles of interferon induction therapy. Am J Med 1999; 107:71S73S. MEDLINE
  • 18
    Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282; 103107. MEDLINE
  • 19
    Bekkering FC, Stalgis C, McHutchison JG, Brouwer JT, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 33; 419423. MEDLINE
  • 20
    Lurie Y, Dusheiko G, Rouzier-Panis R, Glue P. Assesment of optimal dosing frequency of pegylated interferon alfa-2b (Pegintrom) in chronic hepatitis C [Abstract]. Hepatology 2000; 32:1138A.
  • 21
    Zeuzem S, Herrmann E, Lee J-H, Fricke J, Neumann AU, Modi M, Colucci G, et al. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon α2a. Gastroenterology 2001; 120:14381447. MEDLINE
  • 22
    Poynard T, McHutchison J, Goodman Z, Ling AH, Albrecht J, for the ALGOVIRC Project Group. Is “a la carte” combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? Hepatology 2000; 31:211218. MEDLINE